CTLA-4 Blockade Resistance after Relatlimab and Nivolumab

Data were pooled from 36 patients who received the anti–CTLA-4 antibody ipilimumab after metastatic melanoma progression during therapy with nivolumab (anti–PD-1) plus relatlimab (anti–LAG-3) to assess whether immunotherapies that target distinct checkpoints have different mechanisms of action. The...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2022-04, Vol.386 (17), p.1668-1669
Hauptverfasser:	Menzies, Alexander M, Pires da Silva, Ines, Trojaniello, Claudia, Vieu, Elisabeth, Amaria, Rodabe N, Zimmer, Lisa, Lo, Serigne N, Burton, Elizabeth M, Tawbi, Hussein A, Schadendorf, Dirk, Grob, Jean J, Ascierto, Paolo A, Long, Georgina V
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Antigens Antineoplastic Agents, Immunological - adverse effects Antineoplastic Agents, Immunological - therapeutic use CD223 antigen Confidence intervals Cross-resistance CTLA-4 Antigen - antagonists & inhibitors CTLA-4 protein Cytotoxicity Dermatology Drug Resistance Drug Resistance, Neoplasm Hematology Humans Immune checkpoint inhibitors Immune Checkpoint Inhibitors - adverse effects Immune Checkpoint Inhibitors - therapeutic use Immunotherapy Lymphocytes Melanoma Metastases Nivolumab - adverse effects Nivolumab - therapeutic use Oncology PD-1 protein Skin Cancer Treatments in Oncology Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Data were pooled from 36 patients who received the anti–CTLA-4 antibody ipilimumab after metastatic melanoma progression during therapy with nivolumab (anti–PD-1) plus relatlimab (anti–LAG-3) to assess whether immunotherapies that target distinct checkpoints have different mechanisms of action. The findings suggest that cross-resistance emerges when tumors progress with immune checkpoint inhibitors.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMc2119768